Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Nonfiction, Health & Well Being, Medical, Specialties, Toxicology, Medical Science, Pharmacology
Cover of the book Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics by , Elsevier Science
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9780123948236
Publisher: Elsevier Science Publication: June 27, 2013
Imprint: Academic Press Language: English
Author:
ISBN: 9780123948236
Publisher: Elsevier Science
Publication: June 27, 2013
Imprint: Academic Press
Language: English

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics.

  • Provides in-depth coverage of the process of nonclinical safety assessment and comprehensive reviews of each type of biopharmaceutical
  • Contains the most pertinent international regulatory guidance documents for nonclinical evaluation
  • Covers early de-risking strategies and designs of safety assessment programs for novel biopharmaceuticals and vaccines, as well as follow-on biologics or "biosimilars"
  • A multi-authored book with chapters written by qualified experts in their respective fields
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics.

More books from Elsevier Science

Cover of the book Mathematics for Physical Chemistry by
Cover of the book Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging by
Cover of the book Elastomeric Polymers with High Rate Sensitivity by
Cover of the book Developments in Surface Contamination and Cleaning, Volume 7 by
Cover of the book Glycobiology by
Cover of the book Innovations in Food Packaging by
Cover of the book Social Network Analysis of Disaster Response, Recovery, and Adaptation by
Cover of the book Perceptual Learning by
Cover of the book Proceedings of the 31st International Conference on High Energy Physics ICHEP 2002 by
Cover of the book Ethics and Professionalism in Forensic Anthropology by
Cover of the book Foreign Direct Investment in Brazil by
Cover of the book Biomedical Engineering: I Recent Developments by
Cover of the book Basic Molecular Protocols in Neuroscience: Tips, Tricks, and Pitfalls by
Cover of the book Essential Computational Modeling in Chemistry by
Cover of the book Functional Dairy Products by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy